BlackRock
IRLA

BlackRock’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

BlackRock’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Sell
1,702
-664
-28% -$15.3K ﹤0.01% 5283
2026
Q1 		$48K Buy
2,366
+6
+0.3% +$1.2K ﹤0.01% 5142
2025
Q4 		$1.58M Buy
2,360
+633
+37% +$319K ﹤0.01% 4185
2025
Q3 		$563K Buy
1,727
+48
+3% +$16K ﹤0.01% 4429
2025
Q2 		$554K Sell
1,679
-48
-3% -$11K ﹤0.01% 4415
2025
Q1 		$459K Sell
1,727
-512
-23% -$156K ﹤0.01% 4423
2024
Q4 		$837K Buy
2,239
+447
+25% +$134K ﹤0.01% 4264
2024
Q3 		$278K Buy
1,792
+18
+1% +$2.58K ﹤0.01% 4460
2024
Q2 		$266K Buy
1,774
+114
+7% +$20.6K ﹤0.01% 4490
2024
Q1 		$352K Sell
1,660
-18
-1% -$4.47K ﹤0.01% 4468
2023
Q4 		$352K Sell
1,678
-4
-0.2% -$801 ﹤0.01% 4511
2023
Q3 		$377K Sell
1,682
-17
-1% -$4.44K ﹤0.01% 4500
2023
Q2 		$511K Buy
1,699
+79
+5% +$24.6K ﹤0.01% 4477
2023
Q1 		$505K Sell
1,620
-131
-7% -$25.6K ﹤0.01% 4525
2022
Q4 		$223K Sell
1,751
-898
-34% -$150K ﹤0.01% 4823
2022
Q3 		$705K Buy
2,649
+150
+6% +$57.1K ﹤0.01% 4615
2022
Q2 		$1.11M Sell
2,499
-4,521
-64% -$3.2M ﹤0.01% 4499
2022
Q1 		$8.69M Buy
7,020
+35
+0.5% +$47.6K ﹤0.01% 3650
2021
Q4 		$17.6M Buy
6,985
+360
+5% +$2.2M ﹤0.01% 3351
2021
Q3 		$121M Buy
6,625
+202
+3% +$3.21M ﹤0.01% 2089
2021
Q2 		$68.1M Sell
6,423
-390
-6% -$3.27M ﹤0.01% 2491
2021
Q1 		$49.1M Buy
6,813
+2
+0% +$14.4K ﹤0.01% 2622
2020
Q4 		$37.8M Buy
6,811
+2,004
+42% +$17.8M ﹤0.01% 2646
2020
Q3 		$48.1M Buy
4,807
+280
+6% +$2.55M ﹤0.01% 2331
2020
Q2 		$41.9M Buy
4,527
+1,263
+39% +$11.6M ﹤0.01% 2364
2020
Q1 		$29.8M Buy
3,264
+336
+11% +$3.32M ﹤0.01% 2386
2019
Q4 		$32.9M Buy
2,928
+2,151
+277% +$13M ﹤0.01% 2606
2019
Q3 		$3.87M Buy
777
+80
+11% +$492K ﹤0.01% 3554
2019
Q2 		$5.93M Buy
+697
New +$4.16M ﹤0.01% 3481

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's IRLA Position: Q2 2026 in Review

BlackRock reduced its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 28% in Q2 2026, selling an estimated $15.3K and leaving 1,702 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #5283.

BlackRock first reported a position in IRLA in Q2 2019 and has held it in 29 quarters since. The position peaked at $121M in Q3 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • BlackRock held 1,702 shares of IRulya Therapeutics Inc. Common Stock worth $31K as of Q2 2026.
  • BlackRock sold 664 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $15.3K.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5283 holding.
  • BlackRock first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and has held it in 29 quarters since.
  • BlackRock's IRulya Therapeutics Inc. Common Stock position peaked at $121M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.